SHR-1703 is a monoclonal antibody under development for severe asthma. This study is the
first study in patients with asthma. The purpose of this study is to evaluate the safety,
tolerability, pharmacokinetics ，pharmacodynamics and immunogenic characteristics of multiple
subcutaneous injections of SHR-1703 in asthmatic patients.